IGF-1R IS A PREDICTIVE BIOMARKER FOR EGFR TKI (GEFITINIB) RESISTANCE IN NON-SMALL CELL LUNG CANCER USING IHC AND AQUA TECHNOLOGY

被引：0
|
作者：
Kato, Yasufumi [1 ]
Wynes, Murry W. [1 ]
Mascaux, Celine [1 ]
Asuncion, Bernadette G. Reyna [1 ]
Cindy Tran [1 ]
Yoshida, Koichi [2 ]
Matsubayashi, Jun [3 ]
Ohira, Tatsuo [2 ]
Furukawa, Kinya [4 ]
Nagao, Toshitaka [3 ]
Ikeda, Norihiko [2 ]
Hirsch, Fred R. [5 ]
机构：
[1] Univ Colorado Denver, Div Med Oncol, Denver, CO USA
[2] Tokyo Med Univ, Div Thorac Surg, Tokyo 1608402, Japan
[3] Tokyo Med Univ, Div Anat Pathol, Tokyo 1608402, Japan
[4] Tokyo Med Univ, Div Thorac Surg, Ibaraki Med Ctr, Tokyo 1608402, Japan
[5] Univ Colorado Denver, Div Med Oncol & Pathol, Denver, CO USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
AQUA; immunohistochemistry; IGF-1R; Predictive marker;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S449 / S450
页数：2
相关论文
共 50 条
  • [41] Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance
    Li, Fang
    Zhu, Tengjiao
    Cao, Baoshan
    Wang, Jiadong
    Liang, Li
    EUROPEAN JOURNAL OF CANCER, 2017, 84 : 184 - 192
  • [42] Inhitibing GRP78 in non-small cell lung cancer with acquired resistance to EGFR-TKI
    Park, Jaewoo
    Purushothaman, Baskaran
    Hong, Sera
    Choi, Munkyung
    Song, Joon Myong
    Kang, Keon Wook
    CANCER RESEARCH, 2023, 83 (07)
  • [43] VEGFA mediates traditional EGFR-TKI resistance in non-small cell lung cancer with EGFR exon 20 insertions
    Yang, Yaning
    Liu, Chengming
    Yang, Guangjian
    Xu, Haiyan
    Lei, Siyu
    Wang, Yan
    CANCER RESEARCH, 2024, 84 (06)
  • [44] Tumor Microenvironment Remodeling Contributes to the Resistance to EGFR-TKI in EGFR-mutated Non-small Cell Lung Cancer
    Song, X.
    Zhou, C.
    Wu, F.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S362 - S362
  • [45] Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer
    Wu, Shang-Gin
    Shih, Jin-Yuan
    MOLECULAR CANCER, 2018, 17
  • [46] Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer
    Osude, Chike
    Lin, Leo
    Patel, Meet
    Eckburg, Adam
    Berei, Joseph
    Kuckovic, Adijan
    Dube, Namrata
    Rastogi, Aayush
    Gautam, Shruti
    Smith, Thomas J.
    Sreenivassappa, Shylendra B.
    Puri, Neelu
    CELLS, 2022, 11 (10)
  • [47] Role of AKT3 in EGFR-TKI resistance of non-small cell lung cancer.
    Huang, Shih-Hsiang
    Shih, Jin-Yuan
    Chen, Ching-Chow
    MOLECULAR CANCER RESEARCH, 2020, 18 (10) : 55 - 55
  • [48] Pretreatment neutrophil-to-lymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR-mutant Non-small cell lung cancer
    Xu, Cong
    Yao, Xiaojun
    Li, Ting
    Wang, Jue
    An, Bo
    Wang, Jing
    Sui, Xinbing
    Leung, Elaine Lai-Han
    Wu, Qibiao
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2875 - 2883
  • [49] IGF-1R Inhibition in Small Cell Lung Cancer: Role of Brigatinib
    Lakshmanan, I.
    Chaudhary, S.
    Perumal, N. K.
    Batra, S.
    Ganti, A. K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S221 - S221
  • [50] The reversible resistance mechanisms of second generation EGFR-TKI, Dacomitinib, in non-small cell lung cancer
    Haga, Yuya
    Tsutsumi, Yasuo
    CANCER SCIENCE, 2023, 114 : 1071 - 1071
12345